Review finds AI imaging and decision tools help detect cancers earlier and tailor treatment
Study title: Current AI technologies in cancer diagnostics and treatment
By June 2025, a systematic review in Molecular Cancer surveyed current AI technologies across cancer care, from imaging diagnostics with CT, MRI, PET, ultrasound and digital pathology to genomics, liquid biopsies, and therapeutic tools including decision support, treatment planning, drug discovery, radiation therapy and robotic surgery.
Read the study abstract
Cancer continues to be a significant international health issue, which demands the invention of new methods for early detection, precise diagnoses, and personalized treatments. Artificial intelligence (AI) has rapidly become a groundbreaking component in the modern era of oncology, offering sophisticated tools across the range of cancer care. In this review, we performed a systematic survey of the current status of AI technologies used for cancer diagnoses and therapeutic approaches. We discuss AI-facilitated im…

In brief
The synthesis matters because it frames AI as already embedded in detection and personalization workflows rather than speculative, while flagging that privacy, interpretability and regulation will determine how quickly these tools translate into routine, equitable patient management.
Main points
- Systematic survey of AI in oncology covering imaging diagnostics across CT, MRI, PET, ultrasound, and digital pathology.
- Deep learning role in early-stage cancer detection and in genomics, biomarker discovery, and liquid biopsies.
- AI-based clinical decision support, individualized treatment planning, and drug discovery transforming precision therapies.
- Applications evaluated in radiation therapy, robotic surgery, survival prediction, remote monitoring, and clinical trials.
The gain
AI-facilitated imaging and decision support is detecting cancers earlier and making diagnosis and treatment more precise and personalized.
The rundown
The review surveys AI-facilitated imaging diagnostics using computed tomography, magnetic resonance imaging, positron emission tomography, ultrasound, and digital pathology, plus genomics, biomarker discovery, and liquid biopsies for non-invasive diagnosis.
On the therapeutic side it covers AI-based clinical decision support systems, individualized treatment planning, AI-facilitated drug discovery, radiation therapy, robotic surgery, survival predictions, remote monitoring, and AI-facilitated clinical trials, with future directions including federated learning.
Sources
- Peer-reviewedMolecular Cancer2025-06-02
ace

The debate